Viridian Therapeutics recently faced a challenging moment as its investigational antibody for thyroid eye disease, elegrobart, reported results that both met primary objectives and disappointed investor expectations. Although the drug significantly eased the abnormal bulging of the eyes in a late-stage study, the degree of improvement fell short of what analysts had forecasted. Consequently, the company’s stock price plummeted by nearly a third.
Study Overview and Initial Reactions
In the Phase 3 REVEAL-1 study, Viridian focused on evaluating two dosing schedules of elegrobart: one administered every four weeks and the other every eight weeks. A placebo group was included for comparative analysis. The study’s primary endpoint was achieved, with the drug showing a notable effect on proptosis, which is the medical term for the abnormal protrusion of the eyeball.
Despite the positive outcome, Viridian’s stock dropped to $18.53 per share following the announcement. The sharp decline reflected investor disappointment, as expectations had been set higher. Analysts had anticipated a more substantial placebo-adjusted efficacy based on earlier discussions surrounding the drug’s potential.
Analyst Perspectives
Despite the stock market’s reaction, some analysts maintained a positive outlook on Viridian’s findings. Truist Securities characterized the results as encouraging, particularly praising the subcutaneous dosing method, which they believe enhances the drug’s commercial viability. Similarly, William Blair highlighted the potential for regulatory approval and emphasized the significant market opportunity that could arise if Viridian successfully introduces the first subcutaneous treatment for thyroid eye disease.
However, William Blair also pointed out weaknesses in the data, particularly concerning the placebo-adjusted efficacy metrics. The reported proptosis responder rates (PRR) of 36% and 45% for the two treatment schedules fell short of the anticipated 51% to 73% range. This discrepancy raised questions about the robustness of the treatment’s effectiveness.
Efficacy Metrics and Secondary Outcomes
The Phase 3 study revealed that 54% of patients on the monthly dosing schedule experienced a reduction in proptosis by at least 2 mm, while 63% achieved the same result on the eight-week regimen. In comparison, only 18% of the placebo group responded positively, indicating that elegrobart did demonstrate a statistically significant treatment effect.
Despite achieving primary endpoints, the secondary outcome measures presented a mixed picture. The drug registered a significant mean reduction in proptosis compared to placebo, but it failed to outperform placebo in terms of clinical activity scores (CAS). Analysts speculated that a strong placebo response may have influenced these results, complicating the interpretation of the drug’s overall efficacy.
Implications of the Findings
The inability to demonstrate significant improvements in CAS hindered Viridian’s ability to validate other secondary outcomes due to the hierarchical nature of the study’s statistical framework. Nevertheless, the company highlighted some numerical advantages of elegrobart over placebo in terms of resolving diplopia and improving proptosis in the bi-monthly treatment group.
Regarding safety, analysts from Truist noted that elegrobart exhibited a “clean” safety profile, with all treatment-related adverse events classified as non-serious and mild. Some patients experienced hearing-related side effects, including tinnitus, but no significant reductions in hearing were reported. This favorable safety assessment may bolster Viridian’s position when seeking regulatory approval.
Future Prospects
Looking ahead, Viridian is preparing for a second pivotal readout in thyroid eye disease, anticipated in the second quarter of the upcoming year. The company is also on track to submit a biologics license application by the first quarter of 2027, which could pave the way for the drug’s commercial availability.
Key Takeaways
- Viridian’s elegrobart met primary endpoints but fell short of investor expectations regarding efficacy.
- The stock price dropped nearly 33% following the data release, despite some analysts maintaining a positive outlook.
-
The drug demonstrated significant proptosis reduction but faced challenges in secondary efficacy measures.
-
A favorable safety profile may support future regulatory submissions.
In conclusion, while Viridian Therapeutics has made strides with its investigational drug for thyroid eye disease, the mixed results from the latest study highlight the complexities of clinical trials and the cautious optimism that pervades the biotech industry. As the company moves forward, the focus will be on refining its approach and preparing for the upcoming pivotal readout, which could significantly influence its trajectory in the competitive landscape of therapeutic development.
Read more → www.biospace.com